<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update — Live Feed</title><link>https://www.live-feeds.com/feed/sellas-life-sciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/sellas-life-sciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>SELLAS Life Sciences Reports Q3 2026 Results and Corporate Update</title><link>https://www.live-feeds.com/feed/sellas-life-sciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update</link><guid isPermaLink="false">https://www.live-feeds.com/feed/sellas-life-sciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update#u203300</guid><pubDate>Mon, 16 Nov 2026 02:33:34 +0000</pubDate><description>SELLAS Life Sciences released its third quarter 2026 financial results and provided a corporate update. The company&amp;#039;s shares jumped as investors anticipate key leukemia trial results for its lead candidate tambiciclib. A recent study showed the tambiciclib combination demonstrates activity in relapsed or refractory acute myeloid leukemia patients previously treated with venetoclax. The company&amp;#039;s 10-Q filing reveals both financial challenges and growth potential. Investor reaction is being closely monitored as final trial analysis begins.Why it mattersSELLAS Life Sciences is a clinica</description></item>
</channel></rss>